Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells
作者:Anver Basha Shaik、Garikapati Koteswara Rao、G. Bharath Kumar、Nibeditha Patel、Vangala Santhosh Reddy、Irfan Khan、Sunitha Rani Routhu、C. Ganesh Kumar、Immadi Veena、Kunta Chandra Shekar、Madan Barkume、Shailesh Jadhav、Aarti Juvekar、Jyoti Kode、Manika Pal-Bhadra、Ahmed Kamal
DOI:10.1016/j.ejmech.2017.07.056
日期:2017.10
series showed excellent growth inhibition (13b-e, 13h-j, 14c-d, 15 a, 15 c-d, 16b, 16d and 18f; GI50 for MCF-7: 0.4–20 μM). Conjugates 13b, 13c, 13d, 16b and 14d were also evaluated for their cytotoxic activity in human breast cancer cell line (MCF-7). The promising candidates induced cell cycle arrest, mitochondrial membrane depolarization and apoptosis in MCF-7 cells at a 2 μM concentration. Furthermore
癌症已被确定为“所有疾病的皇帝”。近年来,药物化学的重点是鉴定新型抗癌化合物。尽管发现这些化合物似乎是一项艰巨的任务。在目前的研究中,我们合成了40种吡唑并卤代嘧啶缀合物,并探索了它们对60种癌细胞系的细胞毒活性。该系列的15种结合物表现出优异的生长抑制作用(13b-e,13h-j,14c-d,15a,15 cd,16b,16d和18f;MCF-7的GI 50:0.4-20μM)。共轭物13b,13c,13d,还评估了16b和14d在人乳腺癌细胞系(MCF-7)中的细胞毒性活性。有希望的候选物在浓度为2μM的MCF-7细胞中诱导细胞周期停滞,线粒体膜去极化和凋亡。此外,观察到对PI3K / Akt / mTOR通路调节剂(如PI3K,p-PI3K,p - AKT和mTOR)的抑制;以及p -GSK3β和肿瘤抑制蛋白PTEN的上调。我们的研究表明,吡唑并氟哌啶酮结合物可以作为量身定制的癌症治疗剂开发的潜在先导。